Botulinum toxin effect on voluntary and stretch reflex-related torque produced by the quadriceps: an isokinetic pilot study

Neurorehabil Neural Repair. 2012 Jun;26(5):542-7. doi: 10.1177/1545968311423668. Epub 2011 Dec 9.

Abstract

Background: An understanding of the mechanical effects of botulinum toxin type A (BoNT A) on spastic and voluntary muscle contraction may help predict functional responders.

Objective: To compare the effect of BoNT A on the voluntary and stretch reflex-related torques produced by activation of the rectus femoris (RF).

Methods: This was a prospective open study where 15 incomplete spinal cord injury patients, impaired by a stiff-knee gait, with RF hyperactivity in mid-swing quantified by formal gait analysis (GA), were assessed before and after RF BoNT A injection (Botox, 200 UI).

Main outcome measures: Included isokinetic peak torque (and angle at peak torque) at 0° (supine) and 90° (seated) during passive stretch (10 deg/s, 90 deg/s, and 150 deg/s), and voluntary contraction (60 deg/s) of the quadriceps. Secondary measures included impairment by Modified Tardieu Scale (MTS), peak knee flexion and spatial-temporal data by GA, activity (6-minute walking test, timed stair climbing), and discomfort (Verbal Rating Scale).

Results: Voluntary torque decreased (-16%; P = .0004) but with only a trend toward a decrease in stretch reflex-related torque. The angle at spastic torque increased at 90 deg/s (+5°; P = .03), whereas MTS, peak knee flexion (+4°; P = .01), spatial-temporal data, timed stair climbing test (25%; P = .02), and discomfort were significantly improved.

Conclusion: BoNT A appeared to delay the stretch-reflex angle at peak torque, whereas the voluntary torque decreased. After strict patient selection, BoNT A injection into the RF muscle led to improvements in impairment, activity, and discomfort.

MeSH terms

  • Adult
  • Botulinum Toxins, Type A / pharmacology
  • Botulinum Toxins, Type A / therapeutic use*
  • Electromyography
  • Female
  • Gait Disorders, Neurologic / drug therapy*
  • Gait Disorders, Neurologic / etiology
  • Humans
  • Male
  • Middle Aged
  • Muscle Strength Dynamometer
  • Muscle, Skeletal / drug effects*
  • Neuromuscular Agents / therapeutic use*
  • Pilot Projects
  • Prospective Studies
  • Range of Motion, Articular / drug effects
  • Reflex, Stretch / drug effects*
  • Severity of Illness Index
  • Spinal Cord Injuries / complications
  • Spinal Cord Injuries / drug therapy*
  • Torque
  • Treatment Outcome

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A